News News

What is the difference between mild COPD and early COPD?

Date: 2021-05-31
Views: 16

  Many people confuse the concepts of 'early COPD' and 'mild COPD'. Early refers to the time point of COPD progress, while mild refers to the severity of COPD, indicating that airflow is slightly restricted.


  To evaluate the condition of COPD, mild, moderate and severe are more rigorous.


  What is mild chronic obstructive pulmonary disease?


  Research shows that the decline of lung function in patients with mild COPD is faster than that in patients with moderate to severe COPD when acute exacerbation of COPD occurs. The proportion of patients with mild chronic obstructive pulmonary disease is very high, with more than 92% in GOLD 1-2.


  In the stage of mild airflow restriction, although some patients have no obvious symptoms, their exercise endurance, gas diffusion and breathing ability have been impaired in life. This kind of patients are most commonly found in asymptomatic smokers, who may not take the initiative to carry out lung function examination or treatment, so they missed the best treatment period, but this does not mean that he did not suffer from COPD, nor does it mean that there will be no problems later.


  Most patients go to the hospital only when they have symptoms of dyspnea. In patients with mild chronic obstructive pulmonary disease, dyspnea may occur only during high-intensity exercise, which rarely happens at ordinary times. This will also lead to dyspnea. The first choice for patients with mild chronic obstructive pulmonary disease is to reduce the amount of exercise rather than go to the hospital. As time goes by, the disease will gradually worsen. At the same time, it will also lead to cardiovascular disease and skeletal muscle dysfunction. When they actually go to the hospital, it has developed into moderate to severe. Therefore, there is still no particularly good method for early diagnosis and treatment of mild chronic obstructive pulmonary disease.


  How to judge whether it is mild chronic obstructive pulmonary disease?


  Pulmonary function test is the gold standard for diagnosis of COPD, such as FEV1 (forced vital capacity in the first second)/FVC (forced vital capacity) after inhalation of bronchodilator. The decline rate of FEV1 over time is considered as a key variable to assess the gradual decline of pulmonary function in COPD.




  The decrease of FEV1 in patients with mild COPD was greater than that in normal people, and the decrease of FEV1 in patients with respiratory symptoms was greater than that in patients without respiratory symptoms.



  Prevention and treatment of chronic obstructive pulmonary disease


  First of all, it should be clear that there is no drug or surgery that can cure COPD. The goal of COPD treatment is to relieve symptoms and reduce acute exacerbation.


  Standardized treatment is divided into drug treatment and non drug treatment.


  Bronchodilators (including β Receptor agonists, anticholinergic drugs and theophylline drugs are the main measures to relieve symptoms of COPD in stable period. In the acute stage of COPD, bronchodilators are recommended as the initial treatment, combined with glucocorticoids and antibiotics. It is suggested that patients should use drugs regularly for a long time and should not stop taking drugs by themselves.


  In addition, in life, rehabilitation experts also recommend using medical devices to help control the disease, such as oxygen therapy and salt therapy.


  As mentioned above, more than 90% of patients with chronic obstructive pulmonary disease (COPD) are mild. During this period, it is more important to prevent and control the occurrence and development of the disease. Academicians Zhong Nanshan and Wang Chen also stressed that COPD should pay attention to the role of prevention, and non drug prevention and treatment programs are more suitable for such people.


  At present, more and more medical experts recommend the use of saline sol therapeutic apparatus in the prevention, rehabilitation and management of chronic respiratory diseases, especially chronic obstructive pulmonary disease.




  Xinasou Salt Sol Therapeutic Apparatus is the first portable salt therapy device developed by Nanjing Kuancheng Technology Co., Ltd., which integrates natural salt acupoint therapy from nature into one device, and can help prevent, improve, and treat respiratory diseases. The main effects are as follows:


  01 Relieve symptoms


  More than 90% of the patients' symptoms of wheezing, coughing and expectoration were relieved after one week of use, and the difficulty of expectoration after one month of use was significantly reduced, and the sleep quality was improved.


  02 Improvement of pulmonary function


  On the basis of conventional drug treatment, the patients with chronic obstructive pulmonary disease (COPD) and pneumoconiosis improved their pulmonary function indicators after a treatment cycle with the Sinasul salt sol therapeutic instrument, and the maximum ventilation volume per minute (MVV), one second respiratory volume (FEV1) and blood oxygen saturation (SaO2) increased.


  03 Inhibit inflammation


  The inflammatory status of patients with airway infection and pneumonia has been significantly improved after using the Sinasul salt sol therapeutic instrument, and the use of antibacterial drugs has been reduced, with higher safety and better tolerance. The Rehabilitation Department of the Lung Transplantation Rehabilitation Hospital of the First People's Hospital of Wuxi found that the fever symptoms of the patients due to the repeated infection of 'multi drug resistant bacteria' in the body had been effectively controlled during the use of the Sinasul salt sol therapeutic apparatus.


  04 Decrease in the number of acute attacks


  According to the follow-up of the patients who used the Xinashu dry salt aerosol therapeutic instrument, about 70% of the patients with COPD were reduced from two acute attacks in the previous year to once a year, or even did not relapse within a year.


Related Content
On the evening of August 18, 2022, Kuancheng Technology held a symposium on gastrointestinal motility. The theme of the conference was 'Application of gastrointestinal motility detection and treat...
2022 - 08 - 19
Irritable bowel syndrome (IBS) is a chronic functional gastrointestinal disease characterized by abdominal pain, abdominal distension and abdominal discomfort accompanied by changes in defecation habi...
2022 - 07 - 15
'Salt therapy' was recommended by the latest Chinese Expert Consensus on Pneumoconiosis and Lung Rehabilitation!Xinashu rock salt aerosol therapy - a new scheme for lung rehabilitation of pneu...
2022 - 07 - 14
On May 26, 2022, Jiang Wei, deputy director of Jiangsu Drug Administration, visited our company (Nanjing Kuancheng Technology Co., LTD.) to carry out special research on the review and approval of Cla...
2022 - 05 - 27
Functional gastrointestinal diseases, accounting for more than 50% of gastroenterology outpatients. Such as abdominal bloating or flatulence, loss of appetite, early satiety, heartburn, hiccups, belch...
2022 - 05 - 25
(National Service Hotline)
Copyright ©2018 - 2023 Nanjing Kuancheng Technology Co., Ltd
Be lenient towards others and be honest
Share to WeChat friends circle ×
Open WeChat and click "Discovery" at the bottom,
Use "Scan" to share pages with your friends.
Follow us: